In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aileron Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Aileron Therapeutics engineers peptides that contain spiral confirmations called alpha helixes. These spirals are often unstable and fall out of shape--at least when manufactured in the lab. By placing a hydrocarbon staple between the turns in the spiral, Aileron's technology enables peptides to retain their stable conformation, and to arrive at their target destinations in active form. Many of the proteins involved in disease contain these alpha helix structures, and the ability to reproduce synthetic mimics would open up a multitude of therapeutic doors.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091637

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel